MoonLake Immunotherapeutics
MLTX
$39.65
$0.982.53%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 30.32M | 28.03M | 26.05M | 23.61M | 22.32M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 143.09M | 108.54M | 78.40M | 61.01M | 54.12M |
| Operating Income | -143.09M | -108.54M | -78.40M | -61.01M | -54.12M |
| Income Before Tax | -120.96M | -82.45M | -58.02M | -45.68M | -43.98M |
| Income Tax Expenses | 282.20K | 285.40K | 222.20K | 153.60K | 94.30K |
| Earnings from Continuing Operations | -121.24 | -82.74 | -58.24 | -45.84 | -44.08 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | 2.31M | 1.97M | 3.44M | 5.16M | 8.07M |
| Net Income | -118.94M | -80.77M | -54.80M | -40.68M | -36.01M |
| EBIT | -143.09M | -108.54M | -78.40M | -61.01M | -54.12M |
| EBITDA | -141.71M | -108.10M | -77.99M | -60.62M | -53.75M |
| EPS Basic | -1.89 | -1.29 | -0.90 | -0.75 | -0.76 |
| Normalized Basic EPS | -1.16 | -0.79 | -0.54 | -0.43 | -0.41 |
| EPS Diluted | -1.89 | -1.29 | -0.90 | -0.75 | -0.76 |
| Normalized Diluted EPS | -1.16 | -0.79 | -0.54 | -0.43 | -0.41 |
| Average Basic Shares Outstanding | 251.48M | 248.32M | 238.94M | 219.79M | 196.21M |
| Average Diluted Shares Outstanding | 251.48M | 248.32M | 238.94M | 219.79M | 196.21M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
